Pharmaceuticals Brazil

Brazil Cell and Gene Therapy CDMO Market Analysis, 2024–2034

Brazil Cell and Gene Therapy CDMO Market Industry Trends and Forecast to 2034: Segmented by (Service, Product, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Brazil · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $206.2 Mn Estimated value
Estimate 2025 $249.5 Mn 2.9% of the global market
Projected 2034 $1.39 Bn 456% Adds $1.14 Bn over 9 forecast years
CAGR 2025–2034 21.0% Faster than 87% of 180 Pharmaceuticals markets here
Key players 6 +1
  • Brazil is 2.89% of the global market.
  • In Latin America, the largest is Brazil (this report) at $249.5 Mn.
  • Fastest growing: Brazil (this report) at 21% a year.
  • Brazil ranks 1st of 3 by size in Latin America.

Market size projection

Brazil

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$1.14 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Cell and Gene Therapy CDMO Market market size by year, Brazil
YearMarket sizeChange that yearSince 2025
2024 (estimate) $206.2 Mn — —
2025 (base) $249.5 Mn +$43.3 Mn —
2026 (forecast) $301.9 Mn +$52.4 Mn +21%
2027 (forecast) $365.3 Mn +$63.4 Mn +46.4%
2028 (forecast) $442.0 Mn +$76.7 Mn +77.2%
2029 (forecast) $534.8 Mn +$92.8 Mn +114.4%
2030 (forecast) $647.1 Mn +$112.3 Mn +159.4%
2031 (forecast) $783.0 Mn +$135.9 Mn +213.8%
2032 (forecast) $947.4 Mn +$164.4 Mn +279.7%
2033 (forecast) $1.15 Bn +$199.0 Mn +359.5%
2034 (forecast) $1.39 Bn +$240.7 Mn +456%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $8.64 Bn
  2. North America $4.81 Bn
  3. US $3.57 Bn
  4. APAC $1.66 Bn
  5. Europe $1.45 Bn
  6. China $812.4 Mn
  7. Canada $780.3 Mn
  8. Japan $470.1 Mn
  9. Middle East $344.0 Mn
  10. Latin America $339.3 Mn
  11. Germany $268.5 Mn
  12. Brazil (this report) $249.5 Mn
  13. France $226.2 Mn
  14. UK $222.7 Mn
  15. Italy $211.3 Mn
  16. Ecuador $184.2 Mn
  17. Spain $168.4 Mn
  18. Saudi Arabia $166.1 Mn
  19. India $150.8 Mn
  20. Mexico $137.6 Mn
  21. Africa $135.7 Mn
  22. New Zealand $93.5 Mn
  23. Russia $92.5 Mn
  24. Australia $92.9 Mn
  25. South Africa $58.6 Mn
  26. UAE $43.9 Mn
  27. Egypt $25.9 Mn
  28. Philippines $19.4 Mn
  29. Hong Kong $15.3 Mn
  30. Malaysia $12.9 Mn
  31. Thailand $11.5 Mn
  32. Singapore $10.1 Mn
  33. Kenya $5.6 Mn

The Brazil Cell and Gene Therapy CDMO Market Analysis Executive Summary

Cell and gene therapy CDMOs are contract companies that develop and manufacture cell and gene therapies for biotech and pharma firms.

Key segments of the cell and Gene Therapy CDMO market include service (Process Development, Clinical Manufacturing and Commercial Manufacturing) and product (Viral Vectors, Cell Therapies and Plasmid DNA).

Brazil Cell and Gene Therapy CDMO Market Dynamics

Market Growth Drivers

Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the cell and Gene Therapy CDMO market.

Opportunity

Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the cell and Gene Therapy CDMO market.

Market Restraints

Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the cell and Gene Therapy CDMO market. Payers are still working out how to pay for one-time cures.

Competitive Landscape for Cell and Gene Therapy CDMO Market in Brazil

The cell and Gene Therapy CDMO market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Cell and Gene Therapy CDMO Market in Brazil

Cell and Gene Therapy CDMO in Brazil: rules and payment

Medicines need registration with ANVISA, the National Health Surveillance Agency, before sale.⁠[1] The Unified Health System (SUS) gives free public care to everyone, and CONITEC advises which medicines and technologies it adds.⁠[2]

[1] ANVISA. Checked 14 Nov 2026.

[2] CONITEC. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for cell and Gene Therapy CDMO. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Brazil.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Cell and Gene Therapy CDMO right now, from free public sources.

Clinical trials

24 active trials in Brazil

Recruiting, about to start, or running now.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Cell and Gene Therapy CDMO in context

Brazil compared

  • Health spending per person: 1,010 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 4 countries we cover in Latin America.[1]
  • Doctors: 2.36 per 1,000 people (2023). World: 1.86 per 1,000 people (2022). 2nd highest of the 4 countries we cover in Latin America.[2]
  • People aged 65 and over: 11.5% of people (2025). World: 10.4% of people (2025). Highest of the 4 countries we cover in Latin America.[3]

Questions, answered with public data

How many clinical trials on Cell and Gene Therapy CDMO are running in Brazil?
24 studies are recruiting, active or about to start in Brazil.[4]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 13 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 13 Nov 2026.

[4] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Brazil. Retrieved 12 Nov 2026.

Free data on this topic

Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Cell and Gene Therapy CDMO in Brazil? Our analysts can size it for your plan. Talk to us See the public data Health figures for every country, free. Open the Public Health Dashboard
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in Brazil

See all
Same topic, other categories

Related on cell and gene therapy and drug development and manufacturing

See the topic